Regulatory FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program FDAThe U.S.RegulatoryGene TherapyRead full story pharminent April 23, 2026 (Last updated: April 24, 2026) FDA The U.S. RegulatoryGene TherapyRead full story Post navigation Previous: CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug CoverageNext: FDA approves Regeneron’s hearing loss gene therapy Related Stories Regulatory Biopharma industry endorses Pazdur for FDA commissioner role pharminent May 15, 2026 Regulatory With new data, Regenxbio to seek FDA approval of Duchenne gene therapy pharminent May 14, 2026 Regulatory Regulatory round-up: A month of key FDA approvals for cancer drugs pharminent May 14, 2026
